• Diagnosing why single-gene mutation biomarker approaches often underperform, highlighting the need for additional predictors of response

• Presenting combination biomarker concepts, e.g., CCNE-amp + co-alterations and pathway-level logic

• Exploring adaptive enrichment designs for DDR therapies with consideration of prevalence and implementation feasibility